Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling.

Blood - 26 Jul 2012

Lång Emma, Grudic Amra, Pankiv Serhiy, Bruserud Oystein, Simonsen Anne, Bjerkvig Rolf, Bjørås Magnar, Bøe Stig Ove

Abstract excerpt

Arsenic in the form of arsenic trioxide (ATO) is used as a therapeutic drug for treatment of acute promyelocytic leukemia (APL). The mechanism by which this agent cures this disease was previously shown to involve direct interactions between ATO and the promyelocytic leukemia protein (PML), as well as accelerated degradation of the APL-associated fusion oncoprotein PML/retinoic acid receptor α (RARA). Here we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Arsenic Trioxide
Share to Arsenicals

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Promyelocytic, Acute

Share to Nuclear Pore Complex Proteins

Share to Oncogene Proteins, Fusion

Share to Oxides

Share to Promyelocytic Leukemia Protein

Share to Sumoylation

Source

Identifiers

PMID: 22692509
DOI: 10.1182/blood-2011-10-388496

Genes

PML
RARA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling.PMID 22692509Read ↗

Acute promyelocytic leukemia, arsenic, and PML bodiesSemantic proximity Read ↗

Arsenic-induced PML targeting onto nuclear bodies: Implications for the treatment of acute promyelocytic leukemiaSemantic proximity Read ↗

Therapy-induced PML/RARA Proteolysis and Acute Promyelocytic Leukemia CureSemantic proximity Read ↗

Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemiaSemantic proximity Read ↗

Revisiting the differentiation paradigm in acute promyelocytic leukemiaSemantic proximity Read ↗

Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.Semantic proximity Read ↗

Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells.Semantic proximity Read ↗

Cytoplasmic function of mutant promyelocytic leukemia (PML) and PML-retinoic acid receptor-alpha.Semantic proximity Read ↗

Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapiesSemantic proximity Read ↗

Combined Arsenic and Retinoic Acid Treatment Enhances Differentiation and Apoptosis in Arsenic-Resistant NB4 CellsSemantic proximity Read ↗

ATRA Resistance in Acute Promyelocytic Leukemia: Mechanisms Unveiled, Therapies ReimaginedSemantic proximity Read ↗

Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.